Xeris Biopharma Inc. (XERS)
NASDAQ: XERS
· Real-Time Price · USD
4.36
-0.06 (-1.36%)
At close: Jun 13, 2025, 3:59 PM
4.29
-1.61%
After-hours: Jun 13, 2025, 04:20 PM EDT
-1.36% (1D)
| Bid | 4.27 |
| Market Cap | 698.28M |
| Revenue (ttm) | 222.55M |
| Net Income (ttm) | -45.08M |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -15.03 |
| Forward PE | 44.15 |
| Analyst | Strong Buy |
| Ask | 4.48 |
| Volume | 1,568,839 |
| Avg. Volume (20D) | 2,894,174 |
| Open | 4.34 |
| Previous Close | 4.42 |
| Day's Range | 4.30 - 4.41 |
| 52-Week Range | 2.03 - 6.07 |
| Beta | 0.91 |
About XERS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol XERS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for XERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-7.92%
Xeris Biopharma Holdings shares are trading lower....
Unlock content with
Pro Subscription
3 months ago
+9.55%
Xeris Biopharma shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 revenue guidance above estimates.
1 month ago · seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie...
1 month ago · businesswire.com
Xeris Biopharma Reports Record First Quarter 2025 Financial ResultsCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
